Johnson & Johnson announced it would stop selling its legacy baby powder product in the United States and Canada. The company denied allegations its products are responsible for health problems ...

The first time Johnson & Johnson faced a lawsuit due to its talc-based baby powder causing cancer was way back in 1999. Since then, the company has been dealing with litigation, trying its best to get ...

Amivantamab is under clinical development by Johnson & Johnson and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas.

Sales across other products were only down 1%. In 2020 and 2021 (albeit to a lesser degree in 2021), Johnson and Johnson benefitted from some unique, one-time tax benefits. These benefits did not ...

In 2021, Johnson & Johnson unveiled a plan to spin off its consumer products division to focus on pharmaceuticals and medical technology. The company completed the Kenvue spinoff to shareholders ...

The latest trading session saw Johnson & Johnson (JNJ) ending at $145.27, denoting a +0.55% adjustment from its last day's close. This change lagged the S&P 500's 0.73% gain on the day. Meanwhile, the ...

A class action has been filed against Johnson & Johnson accusing it of selling medicines known to be ineffective. If the action is successful, anyone who bought the products in question since 2005 ...